<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03821857</url>
  </required_header>
  <id_info>
    <org_study_id>18-008476</org_study_id>
    <nct_id>NCT03821857</nct_id>
  </id_info>
  <brief_title>Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease</brief_title>
  <official_title>Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are trying to determine whether ovarian hormones are associated with aging
      processes and with the risk of developing Alzheimer's disease in women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed project will enroll 200 women. Each women will have one clinic visit consisting
      of cognitive testing, tests of physical function, questionnaires, and a blood draw. All women
      will also undergo clinical neuroimaging, which includes structural MRI, β-amyloid (Aβ)
      deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of
      neurofibrillary tangles using AV-1451.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18F-Flortaucipir PET imaging</measure>
    <time_frame>1 day</time_frame>
    <description>Cortical 18F-Flortaucipir PET imaging measured once in each participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pittsburgh compound-B PET imaging</measure>
    <time_frame>1 day</time_frame>
    <description>Global cortical SUVR measured once in each participant</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18-F-Flortaucipir</intervention_name>
    <description>Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology</description>
    <arm_group_label>Women</arm_group_label>
    <other_name>11C-Pittsburgh Compound-B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who lived in Olmsted County, Minnesota between 1988 and 2007

          -  Currently aged 55 years and older

          -  More than six months post chemotherapy or major surgery requiring general anesthesia

          -  Willing and able to sign informed consent

        Exclusion Criteria:

          -  Not able to read and speak English

          -  In hospice

          -  Claustrophobic

          -  If undergoing Tau imaging, cannot have QT Prolongation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Mielke, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Amundson</last_name>
    <phone>507-422-4692</phone>
    <email>amundson.sarah@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shannin Renn</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Amundson</last_name>
      <phone>507-422-5627</phone>
      <email>amundson.sarah@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle M Mielke, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michelle M. Mielke, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corticosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

